Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study
المؤلفون المشاركون
Hong, Sung Hoo
Kwon, T.-G.
Chung, Jinsoo
Kim, Sung Han
Kwak, Cheol
Lee, Sang Eun
Kim, Sohee
Nam, Byung-Ho
Kim, Choung-Soo
Seo, Ill Young
Kim, Tae Nam
Seo, Seong Il
Joo, Kwan Joong
Song, Kanghyon
المصدر
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-13، 13ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-02-07
دولة النشر
مصر
عدد الصفحات
13
التخصصات الرئيسية
الملخص EN
We aimed to identify prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in metastatic renal cell carcinoma (mRCC) patients treated with sorafenib.
We investigated 177 patients, including 116 who received sorafenib as first-line therapy, using the Cox regression model.
During a median follow-up period of 19.2 months, the PFS and OS were 6.4 and 32.6 months among all patients and 7.4 months and undetermined for first-line sorafenib-treated patients, respectively.
Clinical T3-4 stage (hazard ratio [HR] 2.56) and a primary tumor size >7 cm (HR 0.34) were significant prognostic factors for PFS among all patients, as were tumor size >7 cm (HR 0.12), collecting system invasion (HR 5.67), and tumor necrosis (HR 4.11) for OS (p<0.05).
In first-line sorafenib-treated patients, ≥4 metastatic lesions (HR 28.57), clinical T3-4 stage (HR 4.34), collecting system invasion (univariate analysis HR 2.11; multivariate analysis HR 0.07), lymphovascular invasion (HR 13.35), and tumor necrosis (HR 6.69) were significant prognosticators of PFS, as were bone metastasis (HR 5.49) and clinical T3-4 stages (HR 4.1) for OS (p<0.05).
Our study thus identified a number of primary tumor-related characteristics as important prognostic factors in sorafenib-treated mRCC patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kim, Sung Han& Kim, Sohee& Nam, Byung-Ho& Lee, Sang Eun& Kim, Choung-Soo& Seo, Ill Young…[et al.]. 2017. Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International،Vol. 2017, no. 2017, pp.1-13.
https://search.emarefa.net/detail/BIM-1139407
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kim, Sung Han…[et al.]. Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International No. 2017 (2017), pp.1-13.
https://search.emarefa.net/detail/BIM-1139407
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kim, Sung Han& Kim, Sohee& Nam, Byung-Ho& Lee, Sang Eun& Kim, Choung-Soo& Seo, Ill Young…[et al.]. Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study. BioMed Research International. 2017. Vol. 2017, no. 2017, pp.1-13.
https://search.emarefa.net/detail/BIM-1139407
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1139407
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر